Novartis AG is a Swiss multinational pharmaceutical company that operates in the Large Pharma sector. Founded in 1996, the company has a strong presence in over 150 countries and employs more than 100,000 people worldwide. Novartis AG is committed to improving the health and well-being of people around the world by providing innovative and high-quality pharmaceutical products and services.
One of the key areas of focus for Novartis AG is decarbonisation. The company recognises the urgent need to reduce greenhouse gas emissions and mitigate the impacts of climate change. To this end, Novartis AG has set ambitious targets to reduce its carbon footprint and transition to renewable energy sources. The company has committed to becoming carbon neutral by 2025 and has set a target to reduce its Scope 1 and 2 emissions by 50% by 2030.
Corporate energy is another area of focus for Novartis AG. The company is committed to improving its energy efficiency and reducing its energy consumption. Novartis AG has implemented a number of energy-saving measures, such as upgrading its lighting systems, improving its HVAC systems, and implementing energy management systems. These measures have helped the company to reduce its energy consumption and lower its operating costs.
Corporate power purchase agreements (PPAs) are another key aspect of Novartis AG's sustainability strategy. The company has signed several long-term PPAs with renewable energy providers to secure a reliable and cost-effective source of renewable energy. These agreements have helped Novartis AG to reduce its carbon footprint and support the development of renewable energy projects. The company has also invested in on-site renewable energy generation, such as solar panels and wind turbines, to further reduce its reliance on fossil fuels.
Renewable energy is a critical component of Novartis AG's sustainability strategy. The company recognises the importance of transitioning to renewable energy sources to reduce its carbon footprint and mitigate the impacts of climate change. Novartis AG has set a target to source 100% of its electricity from renewable sources by 2025 and has made significant progress towards this goal. In 2020, the company sourced 80% of its electricity from renewable sources, up from 70% in 2019.
In addition to its sustainability efforts, Novartis AG is committed to improving access to healthcare and addressing global health challenges. The company has a strong portfolio of innovative pharmaceutical products and services that address a wide range of health issues, from cancer and cardiovascular disease to respiratory and neurological disorders. Novartis AG is also involved in a number of global health initiatives, such as the Novartis Foundation, which aims to improve health outcomes in low- and middle-income countries.
Novartis AG's commitment to sustainability and corporate responsibility is reflected in its corporate governance structure. The company has a dedicated sustainability committee, which oversees the company's sustainability strategy and initiatives. Novartis AG also publishes an annual sustainability report, which provides detailed information on the company's sustainability performance and progress towards its sustainability targets.
In conclusion, Novartis AG is a leading Swiss multinational pharmaceutical company that operates in the Large Pharma sector. The company is committed to sustainability and has set ambitious targets to reduce its carbon footprint and transition to renewable energy sources. Novartis AG's sustainability strategy includes decarbonisation, corporate energy, corporate PPAs, and renewable energy. The company's commitment to sustainability is reflected in its corporate governance structure and annual sustainability report. Novartis AG's innovative pharmaceutical products and services and its involvement in global health initiatives demonstrate its commitment to improving the health and well-being of people around the world.